In a report released today, Alexander Nowak from Craig-Hallum maintained a Buy rating on Sensus Healthcare (SRTS – Research Report). The company’s shares closed last Friday at $4.73.
Nowak covers the Healthcare sector, focusing on stocks such as CVRx, REPRO-MED Systems, and QuidelOrtho. According to TipRanks, Nowak has an average return of -6.5% and a 37.82% success rate on recommended stocks.
Sensus Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $16.83.
See Insiders’ Hot Stocks on TipRanks >>
SRTS market cap is currently $77.56M and has a P/E ratio of 3.24.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sensus Healthcare, Inc. engages in the design, manufacture, and marketing of proprietary medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions. Its main product is SRT-100, a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers and other skin conditions such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.
Read More on SRTS:
